{"id":"W3080672747","doi":"10.1016/j.clml.2020.08.008","title":"Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Research and Development; Takeda Canada; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Janssen Biotech; Roche; GlaxoSmithKline; Amgen","keywords":"Daratumumab; Medicine; Internal medicine; Adverse effect; Oncology; Discontinuation; Multiple myeloma; Lenalidomide","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007528075,0.0008784803,0.001861929,0.000336142,0.0002961571,0.0001263477,0.0007092714,0.0007391777,0.0003257284],"category_scores_gemma":[0.001862276,0.0007065025,0.0005003777,0.001162491,0.0007997314,0.0005137013,0.0003372578,0.001194088,0.000936229],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071633,"about_ca_system_score_gemma":0.0024198,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000445392,"about_ca_topic_score_gemma":0.0002151356,"domain_scores_codex":[0.9926688,0.0005914191,0.001815619,0.0020128,0.001353071,0.001558292],"domain_scores_gemma":[0.9942867,0.00107205,0.0004143247,0.00137835,0.0003401499,0.002508384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01197985,0.00189909,0.7124725,0.0001625893,0.0003810441,0.008696097,0.0002809248,0.00003931042,0.003270863,0.00008020391,0.0009333388,0.2598042],"study_design_scores_gemma":[0.03292043,0.006326657,0.9361957,0.0003227041,0.0001438155,0.0003398636,0.0001965295,0.01347831,0.001206579,0.00003562994,0.008113907,0.0007198197],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991883,0.000599151,0.000102934,0.00158478,0.0002608061,0.00137258,0.0001138142,0.0004056378,0.003677302],"genre_scores_gemma":[0.9908602,0.0003453804,0.004302881,0.002166722,0.0009437441,0.00009725374,0.0007726888,0.00020047,0.0003106487],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2590844,"threshold_uncertainty_score":0.9998416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0549864414527626,"score_gpt":0.3589540105480418,"score_spread":0.3039675690952792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}